



UNIVERSITY OF THE
WITWATERSRAND,
JOHANNESBURG

**ESTIMATION OF SHEDDING TIME IN LABORATORY-CONFIRMED COVID-19
CASES IN SOUTH AFRICA: A POPULATION-BASED RECORD LINKAGE STUDY,
MARCH-DECEMBER 2020**

By

Carroll Tshabane

Student No: 2374447

**A research report submitted to the Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the
degree of Master of Science in Epidemiology (Field epidemiology)**

This research work was supervised by:

Dr Lazarus Kuonza

Dr Nkengafac Villyen Motaze

Mrs Hetani Mdose

SEPTEMBER 2022

DECLARATION

I, Carroll Tshabane, declare that this Research Report is my own unaided work. It is being submitted for the Degree of Master of Science in Epidemiology (Field Epidemiology) at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination to any other University.



(Signature of candidate)

2nd day of August 2022 in Johannesburg, South Africa

DEDICATION

In loving memory of my grandmother

Shalati N'wa Hlupheka Xikoxa

1921- 2021

CONFERENCE PRESENTATION

An abstract for this research was submitted to the 1st International Conference on Public Health in Africa (CPHIA 2021) and was accepted for an oral presentation (**Appendix 2**). The conference was held virtually from 14-16 December 2021. The abstract was titled: Estimation of shedding time in laboratory-confirmed COVID-19 cases in South Africa, 2020.

ABSTRACT

Background

Since the announcement of the first confirmed COVID-19 case in March 2020, South Africa has seen an increase in cases. Determining shedding time is important to inform public health interventions. We aimed to estimate viral shedding time among laboratory-confirmed COVID-19 cases in South Africa.

Methods

A cross-sectional analytic study was conducted using COVID-19 data from 5 March-31 December 2020, obtained from the NMCList and the DATCOV system. These platforms report on laboratory-confirmed and hospitalized COVID-19 patients, respectively. The study consisted of COVID-19 patients with repeat positive PCR tests (at least two positive PCR test results) and who subsequently tested negative. To determine the association between shedding time and predictor variables, multiple linear regression analysis was conducted and a p-value <0.05 was considered statistically significant.

Results

We included 2752 cases that met the inclusion criteria. The 2752 included participants had a total of 8 642 PCR positive test results with a median of 3 positive tests per participant (range: 2 – 11). The majority (74.7%: 2,057/2752) of the participants had 3 consecutive positive tests. About 39.9% (1099/2752) of participants were inpatients and 60.1% (1653/2752) were outpatients. The median shedding time was 17 days(range: 1–128). No significant difference in shedding time was found between males (median:16 days, range:1-128) and females (median:17 days, range:1–94) and between inpatients (median: 16 days, range 1–108) and outpatients (median:17 days, range:1–128). Individuals aged 0–4 years had the lowest shedding time (median:14 days, range:1–72). The shortest shedding time was observed in Eastern Cape with a median of 15 days (range: 1-56) and the longest shedding time was observed in Limpopo province with a median of 21 days (range: 1-39). After adjusting for age, sex and province,shedding time was shorter for hospitalized patients compared to outpatients (coefficient: -0.14, CI: -0.24 — -0.03, P-value: 0.014).

Conclusion

Shedding time varies with admission status (inpatients versus outpatients). We found a significant association between the hospital admission status of COVID-19 patients and shedding time. Further studies are required to explore the association between other comorbidities (such as heart disease, obesity and diabetes mellitus), socio-economic status, level of education, vaccination status and SARS-CoV-2 shedding. In addition, different approaches that can address transmission risk effectively in asymptomatic patients are required to control SARS-CoV-2 infection.

Keywords: COVID-19, South Africa, viral shedding time, laboratory-confirmed, population-based, SARS-COV-2

ACKNOWLEDGEMENTS

I would like to thank my supervisors Dr Villyen Motaze, Dr Lazarus Kuonza and Mrs Hetani Mdose for their supervision, support and guidance during my Master's degree. Special thanks to Dr Alex De Voux and the South African Field Epidemiology Training Program team for the immerse support and motivation.

I would also like to acknowledge the COVID-19 Response Team at the National Institute for Communicable Diseases (NICD) for working tirelessly to respond to the COVID-19 pandemic in South Africa.

My appreciation also goes to my family and friends for their support, encouragement, prayers and belief in me. Lastly, I would like to send my gratitude to Godwin Kalu and Ephordia Thabane for walking this journey with me and for their insightful comments and suggestions in this research.

TABLE OF CONTENTS

DECLARATION	i
DEDICATION	ii
CONFERENCE PRESENTATION.....	iii
ABSTRACT.....	iv
ACKNOWLEDGEMENTS	v
LIST OF FIGURES.....	ix
LIST OF TABLES	x
CHAPTER 1: INTRODUCTION	1
1.1. Background	1
1.1.1. Epidemiology of COVID-19.....	1
1.1.2. COVID-19 in South Africa	2
1.1.3. COVID-19 Viral shedding time.....	3
1.2. Literature Review	4
1.2.1. COVID-19 viral shedding time.....	5
1.2.2. Factors affecting viral shedding time.....	5
1.2.3. Importance of estimating COVID-19 shedding time	6
1.2.4. Laboratory diagnosis.....	6
1.3. Problem Statement	7
1.4. Justification	7
1.5. Research Question.....	7
1.6. Aim.....	8
1.7. Objectives.....	8
References	9
CHAPTER 2 – MANUSCRIPT.....	14

ABSTRACT.....	17
INTRODUCTION	19
METHODS AND MATERIALS.....	20
RESULTS	23
DISCUSSION	24
CONCLUSION.....	28
REFERENCES	30
TABLES	36
FIGURE LEGENDS	41
CHAPTER 3: EXTENDED METHODS.....	44
3.1 Record linkage	44
3.2 Ethical Considerations	44
CHAPTER 4: EXTENDED RESULTS.....	45
CHAPTER 5: OVERALL DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS...	46
5.1 DISCUSSION	46
5.2 LIMITATIONS	47
5.3 CONCLUSION.....	47
5.4 RECOMMENDATIONS	48
REFERENCES	49
APPENDICES	50
Appendix 1: Plagiarism declaration	50
Appendix 2: Conference Abstract.....	51
Appendix 3: Conference Attendance certificate	53
Appendix 4: Turnitin Report	54
Appendix 5: Ethics clearance certificates.....	55

Appendix 6: Clinical Infectious Diseases Guidelines	57
Appendix 7: Declaration- Candidate's contribution to manuscript	70

LIST OF FIGURES

CHAPTER 2

- Figure 1:** Flow chart showing inclusion and exclusion criteria of COVID-19 cases in South Africa, 2020 40
- Figure 2:** Distribution of shedding time of COVID-19 cases in South Africa by sex, 2020 40
- Figure 3:** Distribution of shedding time by age group (years) in South Africa by sex, 2020 40

CHAPTER 4

- Figure 4.1:** Number of positive test results by COVID-19 admission status (hospitalized patients and Outpatients) in South Africa, 2020 44

LIST OF TABLES

CHAPTER 2

Table 1: Baseline characteristics of COVID-19 patients in South Africa, 2020	35
Table 2: Shedding time of laboratory-confirmed COVID-19 cases in South Africa, 2020.....	37
Table 3: Univariate and multivariate analysis of factors affecting viral shedding time in COVID-19 patients in South Africa, 2020.....	38

LIST OF ABBREVIATIONS

CDW	Corporate Data Warehouse
CDC	Centers for Disease Control and Prevention
COVID-19	Coronavirus disease 2019
HIV/AIDS	Human immunodeficiency virus/acquired immune deficiency syndrome
NICD	National Institute for Communicable Diseases
NMC	Notifiable Medical Condition
PHEIC	Public Health Emergency of International Concern
POCT	point-of-care tests
RDT	Rapid Diagnostic Test
RNA	Ribonucleic acid
RT-PCR	Real-time reverse transcription-polymerase chain reaction
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SAFETP	South African Field Epidemiology Training Programme
WHO	World Health Organization

CHAPTER 1: INTRODUCTION

This research report presents findings from a quantitative study that was conducted on coronavirus disease 2019 (COVID-19) patients in South Africa (SA). It provides an overview of COVID-19 viral shedding time and factors associated with shedding time in laboratory-confirmed COVID-19 cases. The introductory chapter will provide background information on COVID-19, describing the burden of disease, disease patterns and its epidemiology. We will further provide a literature review, providing context on shedding time on COVID-19 patients globally. The importance of estimating shedding time and gaps in knowledge will be discussed to justify the research study. To summarize the chapter, the research question, aim and objectives of the study will be listed.

1.1. Background

Wuhan, a city in Hubei province of China recorded its first COVID-19 cases in December 2019. COVID-19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus¹. In early January 2020, COVID-19 cases started to show a gradual increase and by mid-January 2020, the disease had spread to other countries such as Japan, Thailand, and the United States of America. Following the spread of SARS-CoV-2 infections in many countries globally, the disease was announced as a public health emergency of international concern (PHEIC) in January 2020 and was later declared a pandemic in March 2020^{2,3}. As of 5 January 2021, there were 84,233,579 reported COVID-19 cases and 1,843,293 reported deaths globally⁴. To date, there is no cure for COVID-19, however, it can be prevented and controlled through vaccinations, social distancing, wearing of masks and washing or sanitizing hands. As of 05 January 2021, the African region reported 2,852,491 confirmed COVID-19 cases and 67 943 deaths, with a case fatality ratio of 2.4%³. The highest number of SARS-CoV-2 infections in the African region were reported in South Africa.

1.1.1. Epidemiology of COVID-19

COVID-19 spreads through contact with a person infected with SARS-CoV-2, via larger respiratory droplets, through touching contaminated surfaces, and by inhaling small airborne droplets^{5,6}. COVID-19 can stay in the air for some time and can spread through the airborne route however, the contribution of air transmission to the pandemic is unknown^{7,8,9}. Studies have shown that poorly ventilated spaces can act as a potential for airborne transmission^{10,11}. SARS-CoV-2

have also been discovered in specimens such as sperms, blood and stools. Although the virus has been identified in these non-respiratory sites, the role these sites play in COVID-19 transmission is unknown. Different transmission patterns have been reported across Africa, with the majority of the countries reporting community transmissions and some observing clusters and sporadic transmissions. Compared to other continents, Africa is one of the least affected, representing 3.4% of the total reported global cases¹².

COVID-19 affects people of all ages. However, individuals with comorbidities (such as heart disease, obesity and diabetes mellitus) and older people (above 60 years of age) are more vulnerable to infection and have a higher risk of developing severe illness¹³. Signs and symptoms of COVID-19 include body aches, coughing, sore throat, shortness of breath, chills, fever, headache, nausea, diarrhoea, and loss of smell or taste¹⁴. Some people remain asymptomatic after acquiring the infection. However, most people develop mild symptoms of the disease and recover from the illness without medical intervention¹⁵. One in six people have presented with more severe symptoms such as shortness of breath¹³. Nevertheless, the virus can effectively be prevented by wearing a face mask, hand sanitizing, vaccinating and social distancing.

1.1.2. COVID-19 in South Africa

South Africa ranks 15th globally with COVID-19 cases and is the most affected country in the African region even though it has relatively low numbers of deaths^{12,16}. The first COVID-19 case in South Africa was confirmed on 5 March 2020, and on 17 March 2020, the president declared a national state of disaster¹⁷. Since then, lockdown control measures were put in place. These measures included compulsory wearing of face masks, closure of businesses except businesses providing essential services, travel ban, closure of schools and religious centers. Quarantine and isolation measures were also put in place. Asymptomatic people who may have been infected with COVID-19 are placed in quarantine. While isolation is for people who have been infected with SARS-CoV-2 but are not hospitalized¹⁸. Although these control measures were in place, the virus continued to spread throughout the country. By 05 January 2021, there were 1,127,759 cases of COVID-19 and 30 524 deaths in SA. Gauteng province had reported the highest number of cases, representing 27% of total cases, followed by Western Cape at 19.9% and KwaZulu-Natal at 19.8%¹⁹.

COVID-19 continues to have severe economic impacts on the healthcare system²⁰. Healthcare workers have a key role in fighting the COVID-19 pandemic however, they are at a very high risk of being infected by the virus. There is a gradual increase of infections amongst health workers throughout the African continent. Since the beginning of the outbreak, there had been 44 055 reported cases of healthcare workers by 20 October 2020. The most affected healthcare workers were from South Africa, with 27 360 infections¹².

SARS-CoV-2 has been changing over time through mutations causing new variants of the virus. Multiple SARS-CoV-2 variants have been discovered in different countries globally. The variants reported include the Alpha variant (B.1.1.7) which was identified in the United Kingdom (UK); Beta (B.1.351) which was discovered in SA, Delta (B.1.617.2) which was discovered in India and the Gamma variant (P.1) which emerged in Brazil^{21,22}. The Delta variant has been reported to spread faster than other variants and may cause more severe cases compared to other variants²³. The Beta variant was identified in October 2020 in the Eastern Cape, South Africa. Since then, cases caused by this variant has been reported in other countries. Due to significant genetic changes, which is associated with an increased transmission, the Beta variant is a variant of concern²⁴. Variants could be the leading cause of an increase in COVID-19 cases in South Africa which led to a resurgence and affected younger populations during the second wave. The development of SAR-CoV-2 variants has caused an increased risk to public health globally.

COVID-19 vaccines have been developed and rolled out in response to the pandemic to offer protection against the virus to the masses. The Johnson and Johnson vaccine was first administered to healthcare professionals in South Africa in 2020²⁵. A COVID-19 national vaccination program started in February 2021 and the rollout was done in phases covering people aged 12 years and older. Johnson and Johnson, Pfizer-BioNTech and Oxford-AstraZeneca are the only vaccines being administered because they have been reported to provide protection against the Beta variant and other variants²⁶. As of 02 November 2021, 21.1% of the population was fully vaccinated. Studies show that vaccines may reduce the risk of infection and reduce the severity of COVID-19 illness among those that get infected^{7,27}.

1.1.3. COVID-19 Viral shedding time

Various molecular techniques including point-of-care tests (POCT) and central laboratory tests have been made available to diagnose and manage COVID-19 patients. This includes viral and

antibody tests. The World Health Organization (WHO) has recommended that COVID-19 be diagnosed using real-time reverse transcription-polymerase chain reaction (RT-PCR) test²⁸. The PCR test is a molecular test used to detect viral Ribonucleic acid (RNA) which in people infected with SARS-CoV-2 can be detected before, during and after a person presents with symptoms. Studies have used the PCR test to study viral shedding in COVID-19 patients^{29,30}. Viral shedding happens when a virus in an infected person's body is replicated and released into the environment³¹. An individual who is infected with a viral disease is infectious if they are shedding the virus. Therefore, the time and rate at which an infected person sheds the virus are important. For SARS-CoV-2, people shed the virus when they sneeze, talk, cough and through their stools.

During the period of infection, viral shedding time or its duration is used to determine the suitable period of isolation. Viral shedding time is a useful guide for infectivity since it estimates the period of infectiousness. Furthermore, it can be used to establish guidelines for the duration of the isolation period for COVID-19 positive patients, and quarantine for those exposed to COVID-19³². As at the time of reporting, COVID-19 guidelines require asymptomatic patients to isolate for 10 days after testing whereas people with mild disease are required to isolate for 10 days after symptoms onset. Also, people with severe COVID-19 should isolate for 10 days after showing clinical stability³³. Research shows that SARS-CoV-2 transmission begins before symptom onset and peaks early as the disease develops and the risk of transmission reduces thereafter^{34,7}. During the early period of the pandemic, patients infected with COVID-19 were assumed to remain infectious no longer than 14 days after symptom onset. Research shows that the virus can begin shedding before a person starts to show symptoms and shedding increases during or after the onset of symptoms³⁴. Understanding viral shedding time in detail can assist in decreasing the rate of SARS-COV-2 transmission. Therefore, there is a need to estimate shedding time in laboratory-confirmed COVID-19 cases in South Africa.

1.2. Literature Review

This literature review examines various studies that have assessed COVID-19 viral shedding time. It reviews studies that have examined the contributing factors that affect viral shedding time. It also evaluates studies on the importance of estimating COVID-19 shedding time and laboratory diagnosis.

1.2.1. COVID-19 viral shedding time

Viral shedding time is the period during which the virus is released from the body of a person with an infectious disease³⁴. The shedding time of COVID-19 in the population of South Africa has not been studied³⁵. In China, RT-PCR was used to diagnose COVID-19 among hospitalized patients to determine the duration of shedding time. They defined viral shedding time as “the number of days from the onset of the symptoms until the successive negative detection of SARS-CoV-2 RNA³⁶.” To determine shedding time among COVID-19 patients with mild disease in South Korea, viral shedding time was defined as “the duration from the day of diagnosis to the day when a patient displayed negative results for two series of RT-PCR tests, performed at least at a 24-hour interval apart³⁷.” With COVID-19 patients, viral shedding could start before the onset of symptoms³⁴. The median shedding time amongst patients with COVID-19 in China was 11 days³⁸. This was different from Japan where the median viral shedding time of COVID-19 patients was found to be 19 days, ranging between 6-37 days after the first viral detection³⁹. The inconsistency in viral shedding time from different studies across the world may be due to differences in the definition of the RT-PCR test results (negative or positive)⁴⁰.

Studies show that both symptomatic and asymptomatic patients have the potential of transmitting COVID-19 since they can possess similar viral loads^{41,42}. This is evident from a study conducted in Saudi Arabia which found that the mean shedding time of COVID-19 asymptomatic patients was 13.6 days and 16.9 days for symptomatic patients⁴³. Age and comorbidities have been reported to have an impact on symptom severity and clinical outcome⁴⁴. However, pre-symptomatic and asymptomatic cases have been reported to transmit the virus to close contacts and have led to secondary cases⁴⁵. Asymptomatic cases make it difficult to control the transmission of the virus since the duration of their infectiousness is hard to measure.

1.2.2. Factors affecting viral shedding time

Different factors affect viral shedding time in COVID-19 patients. These factors could either slow or increase viral shedding in an individual. Prolonged viral shedding is associated with severe COVID-19 disease which may require ventilation. Studies have reported that shedding time among COVID-19 patients is affected by corticosteroid treatment, fever, long hospital stay and time from onset to hospitalization^{36,46}. Evidence shows that early interventions such as early treatment of COVID-19 patients with symptoms can reduce viral shedding time⁴⁶. Although COVID-19 can

infect anyone, younger age was associated with shorter shedding time whereas older age was associated with longer shedding time³⁰. A study conducted in South Korea reported that comorbidities delay shedding time, also, females shed the virus more than males, although the difference was found to be marginal³⁷.

1.2.3. Importance of estimating COVID-19 shedding time

Several studies have shown that viral shedding time is significant in determining disease transmission^{39,46}. Acquiring more knowledge on the importance of shedding time is important for public health planning, clinical purposes and could benefit society. Considering South Africa's unique epidemiological profile, the population has high HIV/AIDS prevalence, high Tuberculosis incidence and high death rates from non-communicable diseases such as diabetes, making it of study interest. As identified in this literature review, there are some noticeable gaps around shedding time in different contexts and in a large population³². Guidelines for isolation and the duration of quarantine in different countries are made to reflect viral shedding duration.

1.2.4. Laboratory diagnosis

It is fundamental to have rapid and accurate detection of SARS-CoV-2 for treatment and control of the virus. Different diagnostic tests are used to diagnose COVID-19, including molecular tests (such as RT-PCR tests), rapid diagnostic tests (RDT) and antigen tests. The signs and symptoms of the COVID-19 infection are similar to some other infectious respiratory diseases such as influenza, therefore performing laboratory tests on symptomatic people is crucial to identify SARS-CoV-2 infections. Moreover, it is estimated that up to 40% of infected individuals may have no symptoms (subclinical infection) or mild symptoms, yet are still capable of transmitting the virus to others⁴⁷. This means that individuals without obvious signs or symptoms of SARS-CoV-2 infection also require testing. COVID-19 testing can be done in different ways, including detection of viral RNA, detection of viral antigen and detection of antibodies. The PCR test is the standard test for COVID-19 however, it is costly and may take time to receive results. The antigen test is cheaper compared to the PCR test, however, the test is not sensitive and may provide inaccurate results. Antibody tests can identify people who previously tested positive for COVID-19 but were asymptomatic, however, it can miss individuals whose IgM or IgG antibodies are not detectable. The WHO has recommended that laboratories use RT-PCR assays for COVID-19 diagnosis, as it is considered the best test at the moment⁴⁸.

1.3. Problem Statement

To inform infection control, prevention measures and public health policies, it is vital to understand the transmission dynamics of SARS-CoV-2. Population-level information on shedding time and factors affecting the duration of SARS-CoV-2 infection is lacking. This information could be used to understand the association between viral shedding and infectivity and the effectiveness of using a PCR test for infectiousness or re-infection. Estimating viral shedding time is vital since shedding can be utilized as a proxy for infectiousness⁴⁶. Control measures such as quarantine and wearing of masks have been put in place in South Africa. However, the average shedding time in the South African population is unknown and there is a lack of thorough research on the duration of infectiousness for SARS-CoV-2³⁵. Also, there is no routine test available to measure infectiousness. This means that determining viral shedding time and understanding the associated predictors will play a significant role in informing control and prevention measures in COVID-19 patients.

1.4. Justification

Numerous studies have been conducted globally to estimate the duration of SARS-CoV-2 viral shedding however, no study has estimated viral shedding time for laboratory-confirmed COVID-19 cases in the South African population. Since SA reported the highest numbers of COVID-19 infections on the African continent, it is important to better understand the transmission dynamics of the virus in the population. The results from this study will assist in refining infection control strategies such as contact tracing and isolation or quarantine, and assist in understanding the potential difference of positive PCR tests over time. The results may further be utilized in facilitating early treatment and intervention, leading to a decrease in the incidence and mortality due to coronavirus disease.

1.5. Research Question

What is the viral shedding time of SARS-CoV-2 among laboratory-confirmed COVID-19 cases in South Africa?

1.6. Aim

To estimate the viral shedding time among laboratory-confirmed COVID-19 cases in South Africa.

1.7. Objectives

Objective 1: To describe the clinical and epidemiological characteristics of patients with COVID-19 in South Africa, 2020.

Objective 2: To determine the shedding time of laboratory-confirmed COVID-19 cases in South Africa, 2020.

Objective 3: To determine factors affecting viral shedding time in COVID-19 patients in South Africa.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents*. 2020;55(3):105924.
2. World Health Organization (WHO). COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum [Internet]. [cited 2021 Feb 8]. Available from: [https://www.who.int/publications/m/item/COVID-19-public-health-emergency-of-international-concern-\(pheic\)-global-research-and-innovation-forum](https://www.who.int/publications/m/item/COVID-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum)
3. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. 2020;91:157–60.
4. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2021 Jan 5]. Available from: <https://covid19.who.int/>
5. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Vol. 188, *Environmental Research*. Academic Press Inc.; 2020. p. 109819.
6. Morawska L, Tang JW, Bahnfleth W, Bluyssen PM, Boerstra A, Buonanno G, et al. How can airborne transmission of COVID-19 indoors be minimised? Vol. 142, *Environment International*. Elsevier Ltd; 2020. p. 105832.
7. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. *N Engl J Med*. 2021;385(8):759–60.
8. Wilson N, Corbett S, Tovey E. Airborne transmission of COVID-19. *BMJ*. 2020;370:10–1.
9. Borak J. Airborne Transmission of COVID-19. *Occup Med (Chic Ill)*. 2020;70(5):297–9.
10. Centers for Disease Control and Prevention (CDC). Scientific Brief: SARS-CoV-2 Transmission | CDC [Internet]. [cited 2021 Nov 8]. Available from:

<https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html>

11. World Health Organization (WHO). Transmission of SARS-CoV-2: implications for infection prevention precautions [Internet]. [cited 2021 Nov 8]. Available from: <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions>
12. World Health Organization (WHO). Situation reports on COVID-19 outbreak - Sitrep 32, 07 October 2020 | WHO | Regional Office for Africa [Internet]. [cited 2021 Feb 8]. Available from: <https://www.afro.who.int/publications/situation-reports-COVID-19-outbreak-sitrep-32-07-october-2020>
13. Panyod S, Ho CT, Sheen LY. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. Vol. 10, Journal of Traditional and Complementary Medicine. National Taiwan University; 2020. p. 420–7.
14. Centers for Disease Control and Prevention. Symptoms of Coronavirus | CDC [Internet]. [cited 2021 Jan 20]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>
15. Zhang F, Gan R, Zhen Z, Hu X, Li X, Zhou F, et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Signal Transduct Target Ther. 2020 Dec 1;5(1).
16. World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2021 Feb 8]. Available from: <https://covid19.who.int/table>
17. National Institute for Communicable Diseases. FIRST CASE OF COVID-19 CORONAVIRUS REPORTED IN SA | NICD [Internet]. [cited 2021 Feb 8]. Available from: <https://www.nicd.ac.za/first-case-of-COVID-19-coronavirus-reported-in-sa/>
18. Centers for Disease Control and Prevention. Isolate If You Are Sick | CDC [Internet]. [cited 2021 Feb 8]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/isolation.html>

19. National Institute for Communicable Diseases. LATEST CONFIRMED CASES OF COVID-19 IN SOUTH AFRICA (05 JAN 2021) | NICD [Internet]. [cited 2021 Feb 8]. Available from: <https://www.nicd.ac.za/latest-confirmed-cases-of-COVID-19-in-south-africa-05-jan-2021/>
20. Mbunge E. Effects of COVID-19 in South African health system and society: An explanatory study. *Diabetes Metab Syndr Clin Res Rev*. 2020 Nov 1;14(6):1809–14.
21. Hirotsu Y, Omata M. Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan. *J Infect*. 2021 Jun 1;82(6):276.
22. Luring AS, Malani PN. Variants of SARS-CoV-2. *JAMA - J Am Med Assoc*. 2021;326(9):880.
23. Centers for Disease Control and Prevention (CDC). Delta Variant: What We Know About the Science | CDC [Internet]. [cited 2021 Nov 8]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html>
24. Control EC for DP and. SARS-CoV-2 variants of concern as of 4 November 2021 [Internet]. [cited 2021 Nov 8]. Available from: <https://www.ecdc.europa.eu/en/COVID-19/variants-concern>
25. Dzinamarira T, Nachipo B, Phiri B, Musuka G. COVID-19 vaccine roll-out in south africa and zimbabwe: Urgent need to address community preparedness, fears and hesitancy. *Vaccines*. 2021;9(3):1–10.
26. Belongia EA, Coleman LA, Donahue JG. Effectiveness of the BNT162b2 COVID-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *Jama*. 2007;2728–31.
27. Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. *Inflammopharmacology*. 2021;29(5):1357–60.
28. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Vol. 162, *Diabetes Research and Clinical Practice*. Elsevier Ireland Ltd; 2020. p. 108142.
29. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba

- N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021 121. 2021 Jan 11;12(1):1–6.
30. Phillips SP, Wei X, Kwong JC, Gubbay J, Schwartz KL, Majury A, et al. Duration of SARS-CoV-2 shedding: A population-based, Canadian study. *PLoS One*. 2021 Jun 1;16(6):e0252217.
 31. Centers for Disease Control and Prevention. Duration of Isolation and Precautions for Adults with COVID-19 | CDC [Internet]. [cited 2021 Feb 8]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>
 32. Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. *Infect Dis Heal*. 2020;25(3):210–5.
 33. National Department of Health. Guidelines for symptom monitoring and management of essential workers for COVID-19 related infection. 2020;2019(43600):1–8.
 34. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020;26(5):672–5.
 35. National Institute for Communicable Diseases. COVID-19 re-infection: your questions answered | NICD [Internet]. [cited 2021 Jan 12]. Available from: <https://www.nicd.ac.za/COVID-19-re-infection-your-questions-answered/>
 36. Qi L, Yang Y, Jiang D, Tu C, Wan L, Chen X, et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. *Int J Infect Dis*. 2020;96:531–7.
 37. Kim B, Sohn JW, Nam S, Sohn JW, Choi WS, Kim HS. Factors associated with the delayed termination of viral shedding in COVID-19 patients with mild severity in south korea. *Med*. 2020 Dec 1;56(12):1–11.
 38. Fang Z, Zhang YJY, Hang C, Ai J, Li S, Zhang W, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. *Int J Infect Dis*. 2020;96(1):1–10.

39. Miyamae Y, Hayashi T, Yonezawa H, Fujihara J, Matsumoto Y, Ito T, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. *Int J Infect Dis.* 2020;97:293–5.
40. Karia R, Nagraj S. A Review of Viral Shedding in Resolved and Convalescent COVID-19 Patients. *SN Compr Clin Med.* 2020;2(11):2086–95.
41. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral Shedding among Asymptomatic and Symptomatic Patients with SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. *JAMA Intern Med.* 2020;180(11):1447–52.
42. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission from People without COVID-19 Symptoms. *JAMA Netw Open.* 2021;4(1):1–8.
43. AlJishi JM, Alhajjaj AH, Alkhabbaz FL, AlAbduljabar TH, Alsaif A, Alsaif H, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. *J Infect Public Health.* 2021;14(1):6–11.
44. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. *Sn Compr Clin Med.* 2020 Aug;2(8):1.
45. Bender JK, Brandl M, Höhle M, Buchholz U, Zeitlmann N. Analysis of Asymptomatic and Presymptomatic Transmission in SARS-CoV-2 Outbreak, Germany, 2020. *Emerg Infect Dis.* 2021 Apr 1;27(4):1159.
46. Han J, Shi LX, Xie Y, Zhang YJ, Huang SP, Li JG, et al. Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration. *Epidemiol Infect.* 2020;148.
47. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Vol. 173, *Annals of internal medicine.* NLM (Medline); 2020. p. 362–7.
48. Agarwal V, Venkatakrishnan AJ, Puranik A, Kirkup C, Lopez-Marquez A, Challener DW, et al. Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity. *medRxiv.* 2020;

CHAPTER 2 – MANUSCRIPT

This chapter presents a manuscript written using the journal author guidelines for Clinical Infectious Diseases. The formatting of the journal article may differ from the rest of the research report to comply with the author guidelines of the journal to which we intend to submit the article. The journal guidelines are included in the appendices (**Appendix 6**).

Estimation of shedding time in laboratory-confirmed COVID-19 cases in South Africa: A population-based record linkage study, March-December 2020

Carroll Tshabane^{1,2}, Villyen Motaze^{1,3}, Hetani Mdose^{1,2,4}, Alfred Musekiwa^{1,4}, Lazarus Kuonza^{1,2,4}

¹National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa

² School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa

³Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

⁴School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

Correspondence to: Carroll Tshabane, National Institute for Communicable Diseases, 1 Modderfontein Road, Sandringham 2131, Johannesburg, South Africa. Email: ctshabane@gmail.com; Tel: +2711 386 6400

Summary: This cross-sectional analytic study reports shedding time among PCR-confirmed COVID-19 cases in South Africa from March to December 2020. The median shedding time was 17 days (range: 1–128). Disease severity (admission status) was associated with shedding time.

ABSTRACT

Background

In South Africa, COVID-19 cases are notified through the NMCList platform while hospitalized cases are reported on the DATCOV platform. It is crucial to estimate the duration of SARS-CoV-2 shedding to inform public health interventions. We aimed to estimate viral shedding time among laboratory-confirmed COVID-19 cases in South Africa.

Methods

We analyzed COVID-19 PCR results reported on the NMCList and DATCOV platforms from 5 March to 31 December 2020. We included cases with at least 2 consecutive positive PCR tests and a subsequent negative test. We performed multiple linear regression to determine the association between shedding time and predictor variables (age, sex, admission status and province). A p-value below 0.05 was considered to be statistically significant.

Results

We included 2752 cases that met the inclusion criteria. About 39.9% (1099/2752) of participants were inpatients and 60.1% (1653/2752) were outpatients. The median shedding time was 17 days (range: 1–128). There was no significant difference in shedding time between males (median:16 days, range:1-128) and females (median:17 days, range:1–94) and between hospitalized patients (median: 16 days, range 1–108) and outpatients (median:17 days, range:1–128). Individuals aged 0-4 years had the lowest shedding time (median:14 days, range:1–72). After adjusting for age, sex and province, shedding time was shorter for hospitalized patients compared to outpatients (coefficient: -0.14, CI: -0.24 — -0.03, P-value: 0.014).

Conclusion

Shedding time differs between hospitalized and outpatients. Further studies are required to explore the association between comorbidities and SARS-CoV-2 shedding time.

Keywords: COVID-19, SARS-CoV-2, viral shedding time, South Africa, population-based

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The virus was first identified in Wuhan, China in December 2019. COVID-19 has spread globally, causing a global pandemic [2]. On 5 March 2020, South Africa reported its first confirmed COVID-19 case [3]. Despite strict measures such as lockdown and compulsory wearing of masks put in place to control the epidemic, the virus has continued to spread. Viral shedding time is a useful guide for infectivity and can be used to establish the duration of isolation, quarantine and inform contact tracing guidelines [4]. With the polymerase chain reaction (PCR) test being the best test available for COVID-19 diagnosis, several studies have used it to estimate viral shedding time [5,6,7]. The Republic of Korea reported a median shedding time of 15 days among COVID-19 patients [8]. This was different from Japan where the median viral shedding time of COVID-19 patients was reported to be 19 days [9]. Studies show that both symptomatic and asymptomatic patients have the potential of transmitting the COVID-19 [8,10]. This is evident from a study conducted in Saudi Arabia which found that the mean shedding time of COVID-19 asymptomatic patients was 13.6 days and 16.9 days for symptomatic patients [11]. Factors affecting shedding time include the severity of disease, age, sex, comorbidity, timeliness of treatment and COVID-19 symptoms such as fever [6,7,12,13]. Age and comorbidities have been reported to have an impact on symptom severity and clinical outcome [14].

South Africa has reported the highest number of SAR-CoV-2 infections in Africa, therefore determining viral shedding time is important to understand the transmission dynamics of the disease within the population. This study aimed to estimate viral shedding time among laboratory-confirmed COVID-19 cases in South Africa.

METHODS AND MATERIALS

Study design and procedures

We performed a cross-sectional analytic study using COVID-19 data obtained from the COVID-19 Notifiable Condition List (NMCList). The study included laboratory results from public and private clinical laboratories in South Africa that reported COVID-19 test results to the NMCList database. The study population consisted of all laboratory-confirmed COVID-19 patients reported to the NMCList database from March to December 2020. We included laboratory-confirmed COVID-19 patients with repeat positive PCR tests (at least two positive PCR test results) and subsequently tested negative. A person should have done consecutive testing no longer than 14 days between the repeat positive PCR tests. We excluded positive cases that were tested using antigen tests and cases that took a repeat test after 14 days of continuing positivity.

Data sources

COVID-19 test results are reported to the NMCList database hosted by the National Institute for Communicable Diseases (NICD). COVID-19 is a category 1 Notifiable Medical Condition (NMC) with a requirement of immediate reporting upon clinical suspicion or laboratory diagnosis followed by a written notification within 24 hours. Clinical data of patients tested for COVID-19 are collected using the NMC reporting platform, which is a national reporting system in South Africa. Both RT-PCR and antigen COVID-19 test results are stored in the NMCList database and reported to the National Department of Health (NDoH). Individuals who have multiple test results are identified using a unique identifier (case_id). Other variables stored in the NMCList include personal identifiers (name, surname, date of birth, sex, national identity number), demographic information (physical address), and health facility information. Data from the NMCList is stored in the NICD surveillance data warehouse.

The DATCOV system is an active, prospective sentinel surveillance programme for COVID-19 in South Africa. This online platform enables private and public healthcare facilities to submit hospital admissions data for COVID-19 patients. COVID-19 admissions trends are monitored and the epidemiology of the disease in hospitalized patients within the country is described. Admission status (hospitalized or outpatient) was used as a proxy to determine disease severity. Hospitalized patients were defined as patients with severe disease and outpatients as patients with mild disease.

Data collection

We extracted data from the NMCList and DATCOV databases. It was assumed that COVID-19 cases that were not in the DATCOV database were not hospitalized. The patients' national identity number was used to link cases between the NMCList and DATCOV databases.

Case Definitions

COVID-19 case: "A confirmed case of COVID-19 is a person with laboratory confirmation of SARS-CoV-2 infection (using an RT-PCR assay), irrespective of clinical signs and symptoms between March and December 2020" [15].

Negative result: A person with a negative SARS-CoV-2 laboratory test using an RT-PCR assay.

Variables

Outcome Variable: The outcome variable is COVID-19 viral shedding time measured in days.

Viral shedding time (days) was defined as the period from the date of specimen collection for the first positive PCR test to the date of specimen collection for the last positive test prior to a first negative PCR test. The date of specimen collection for the first positive test was subtracted from

the date of specimen collection for the last positive test to obtain the shedding time (in days). The date of onset of viral shedding was defined as the day the specimen of a case was collected since laboratory data had no variable for the date of symptom onset. This approach catered for individuals who would have been symptomatic or asymptomatic.

Explanatory variables included sex, age, province, number of tests done and the severity of COVID-19 (hospitalized patients versus outpatient).

Statistical analysis

Data were analyzed using STATA 15 (Version 15, StataCorp, College Station, Texas).

Characteristics of study participants were reported using descriptive statistics. Categorical variables (age groups, sex, admission status and province) were presented using absolute numbers and percentages. Normally distributed continuous variables (age) were reported using means and standard deviations while medians and ranges were used when continuous variables were not normally distributed (shedding time). Initially, simple linear regression was done to assess the association between the dependent variable (shedding time) and each predictor variable. Predictor variables with a p-value of <0.1 from the simple linear regression were added to the multiple linear regression model. We determined differences in shedding time by age, sex, hospital admission status and province. We reported effect estimates and 95% confidence intervals. We considered a p-value of less than 0.05 as statistically significant.

Ethical Considerations

We received ethics approval from the Human Research Ethics Committee at the University of the Witwatersrand (Clearance Certificate No. M210443).

RESULTS

Characteristics of the study population

There were 1 057 161 COVID-19 cases reported from 5 March to 31 December 2020 in South Africa. Out of these cases, 2752 (0.26%) met the inclusion criteria. **Figure 1** shows details of the participant selection process. The 2752 included participants had a total of 8 642 PCR positive test results with a median of 3 positive tests per participant (range: 2 – 11). The majority (74.7%: 2,057/2752) of the participants had 3 consecutive positive tests. **Table 1** describes the characteristics of the study population. There were more males than females (53% versus 47%). Participants ages ranged from 0-99 years, with a mean of 46.4 years (SD: 17.4). Individuals aged 35-44 years were the most frequently represented age group (22.9%) while 0-14 year-olds were the least frequent age group (1.2%). Of all the participants, 39.9% were inpatients and 60.1% were outpatients. Gauteng province had the highest number of participants with 987 (35.9%) cases and Northern Cape had the lowest with 39 (1.4%) cases.

Shedding time in COVID-19 patients

Table 2 summarizes the distribution of shedding time by age, sex, province, and admission status. The median duration of viral shedding was 17 days, ranging from 1 to 128 days from the date of specimen collection or symptoms onset date. There was no significant difference in shedding time between males (median:16 days, range:1-128) and females (median:17 days, range:1-94) (**Figure 2**). Viral shedding time between inpatients (median: 16 days, range 1-108) and outpatients (median:17 days, range:1-128) did not differ much either. Also, there was no significant difference in shedding time between age groups. Individuals aged 0-14 years had the lowest shedding time (median:14 days, range:1-72) while those aged 25-34 years had the highest shedding time (median:18 days, range:1-128) (**Figure 3**). The shortest shedding time was

observed in Eastern Cape with a median of 15 days (range: 1-56) and the longest shedding time was observed in Limpopo with a median of 21 days (range: 1-39).

Factors associated with COVID-19 shedding time

In **Table 3**, we assessed factors associated with shedding time in COVID-19 patients in South Africa. We applied simple and multiple linear regression to compare the association between predictor variables (age, sex, province and hospital admission status) and SARS-CoV-2 shedding time. Following unadjusted analysis, shedding time did not vary with sex and age group.

Regarding province of residence, Eastern Cape was considered the baseline for comparisons. Shedding time in Free State and Northern Cape did not differ from shedding time in Eastern Cape. However, shedding time was longer in KwaZulu-Natal (coefficient: 0.3, CI: 0.1 – 0.5, P-value: <0.001), Limpopo (coefficient: 0.6, CI: 0.3 – 0.9, P-value: <0.001), Mpumalanga (coefficient: 0.5, CI: 0.2 – 0.8, P-value: 0.002), North West (coefficient: 0.4, CI: 0.1 – 0.7, P-value: 0.012) and Western Cape (coefficient: 0.3, CI: 0.1 – 0.5, P-value: 0.001). Shedding time was shorter among hospitalized patients compared to outpatients (coefficient: -0.1, CI: -0.2 – -0.04, P-value: 0.007).

After adjusting for age, sex and province, shedding time remained shorter for hospitalized patients compared to outpatients (coefficient: -0.14, CI: -0.24 – -0.03, P-value: 0.014). Province, sex and age, were not associated with shedding time.

DISCUSSION

This study aimed to estimate the viral shedding time among laboratory-confirmed COVID-19 cases in South Africa. We found that the median shedding time in our sample was 17 days from symptoms onset date or date of specimen collection. A study conducted on the Canadian population [16] found that the median shedding time was 19 days which is 2 days more than

our findings among the South African population. Another study conducted in the United States of America reported a median shedding time of 21 days within their population, which is higher than the shedding time we found within our population [17]. The difference in shedding time between South Africa, Canada and the United States could be due to the difference in population characteristics in these geographic locations. Our findings are similar to those reported in a study conducted in China which found that the median shedding time among adults was 17 days [6]. Although our study shows a similar median shedding time to that of China, our study included both children and adults and covered a wider population whereas the study conducted in China only included adults.

Shedding time ranged from 1 to 128 days from the date of specimen collection or symptoms onset date. Our study did not show a significant difference in the median shedding time between males and females and between hospitalized and outpatients. Our study is supported by another study that found no significant difference in the median shedding time between males and females and further reported that prolonged shedding was not affected by signs and symptoms of COVID-19 [18]. Another study conducted on outpatients and inpatients in the United States of America found that the viral shedding time of inpatients was similar to that of outpatients [17].

Our study also shows no significant difference in shedding time between age groups. Age group 0-14 years had a median shedding time of 14 days which was the lowest among other age groups. Age group 25-34 reported the highest shedding time with a median shedding time of 18 days. The slight difference in shedding time between age groups might be due to the fact that people live in families and communities where people of different age groups live together, allowing for transmission to happen within different age groups. Our study found that South

African children had a lower shedding time compared to children in South Korea who were reported to have an average shedding time of 17.6 days [19]. Another study found that children less than 18 years had a shorter shedding time compared to other age groups [17]. The study further highlights that viral shedding can happen in children presenting with symptoms and those without symptoms, with a shedding time of up to 3 weeks (21 days). Children and young adults are more likely to have mild disease and less likely to have severe or fatal COVID-19 compared to adults [18]. The age-related difference in severity of COVID-19 in children and adults could be due to the fact that children have lower intensity of exposure to SARS-CoV-2. Furthermore, it is thought that children have a stronger innate immune system, which acts as the first line of defense against SARS-CoV-2 [19]. Older adults usually have a higher prevalence of comorbidities, such as obesity, hypertension and heart disease, which are associated with severe COVID-19 compared to children [20]. Although children can also experience severe clinical disease, they are less affected by COVID-19 than adults.

In general, testing of is patterns in children are different from those in adults and children are most often tested when they are symptomatic or a contact of a case. SARS-CoV-2 is shed when talking, coughing, sneezing, or even exhaling. Studies also show that the virus can be shed via feces and urine and can continue for several weeks [23,24]. This makes it possible for the virus to spread in schools where they share classrooms and objects and in pre-schools where children are taken care of by the same teacher.

Viral shedding can continue for longer periods in some patients. Two cases had a shedding time greater than 100 days. The cases were a 77-years-old inpatient male who shed the virus for 108 days and a 34-year-old outpatient male who shed the virus for up to 128 days. A study of 38 COVID-19 patients with prolonged shedding reported that the longest shedding time they observed was 118 days, and was a 77-year-old male [25]. It is difficult to determine why

certain individuals have such prolonged shedding and further research is needed to better understand this.

A study conducted on six COVID-19 patients shows that prolonged viral shedding can be observed in both asymptomatic and severe patients [25]. Severe disease, comorbidities, socioeconomic status, old age and male sex have been reported as factors associated with prolonged SARS-CoV-2 viral shedding [13,16,21,26]. Other studies have reported prolonged shedding, however, prolonged shedding was mainly reported in patients with severe disease [18]. The Centers for Disease Control and Prevention (CDC) recommends that people with possible COVID-19 exposure should quarantine for 14 days and people who test positive should isolate for 10 days from the date of symptoms onset [27]. South Africa however recommends 10 days of isolation or quarantine for asymptomatic patients, and patients with mild, moderate or severe disease [28]. Of people infected with COVID-19, only 20% experience moderate or severe disease and require hospitalization. Eighty per cent experience mild COVID-19 and isolate from home. Also, it has been reported that asymptomatic or pre-symptomatic cases are the main drivers of COVID-19, accounting for about 50% of new COVID-19 infections[26].

Therefore, it is important to monitor viral shedding in patients with mild disease because they can shed the virus longer and could potentially be a source of future COVID-19 outbreaks. Our findings indicate that infection control strategies provided by CDC and the NDoH should take into account prolonged shedding and its impact on disease transmission.

Our study found a significant association between hospitalized patients and shedding time. Inpatients had 1 day less shedding time compared to hospitalized patients. Studies show that COVID-19 patients who are hospitalized usually have COVID-19 symptoms, comorbidities and

are more likely to be older [30,31,32,34]. In line with another study, our study found no association between age and shedding time [35]. However, some studies have reported that older age is associated with prolonged shedding [36,37]. Furthermore, male sex has been reported to have an association with prolonged shedding however, our study found no association between sex and viral shedding time [38]. Several studies have reported no association between viral shedding time and sex [37, 39,40]. Although the variable province was not statistically significant, the association between shedding time and province varied. KwaZulu-Natal, Gauteng, Limpopo, North West, Mpumalanga, and Western Cape had a significant association with shedding time. The differences in shedding time between different regions may be due to differences in comorbidities, socioeconomic status, type of test used, sample size and disease severity.

Our study had some limitations. Firstly, data received from the NMCList did not include clinical information about the cases. Secondly, due to the secondary nature of the study, we could not get certain variables that could have assisted in determining other factors affecting shedding time within the population. Lastly, viral shedding before symptom onset and before testing was not measurable using the data we obtained. It is likely that viral shedding occurs beyond the time points we have described. It is also possible that the shedding time presented in our study is likely to be an underestimate of the true shedding time in the population.

CONCLUSION

The duration of viral shedding within the population of South Africa varies from 1 to 128 days. Hospitalized patients are associated with SARS-CoV-2 shedding time. Our findings indicate that infection control strategies should take into account factors affecting shedding time such as disease severity.

NOTES

Conflict of interest

No conflict of interest declared

Acknowledgements

We would like to acknowledge the NICD COVID-19 Outbreak Response Team and the South African Field Epidemiology Training Programme for their support and guidance.

We would also like to acknowledge Stanford Kwenda, Ndivhuwo Munava, Lincoln Darwin, Tsumbedzo Mukange and Trevor Bell.

Author contributions

Carroll Tshabane and NV Motaze conceived the study question. All authors reviewed and approved the study protocol.

Carroll Tshabane conducted the study, analyzed the data and drafted the manuscript. Co-Authors were responsible for study supervision and reviewing the manuscript.

REFERENCES

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents* 2020; 55:105924.
2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed* 2020; 91:157–160.
3. National Institute for Communicable Diseases. FIRST CASE OF COVID-19 CORONAVIRUS REPORTED IN SA | NICD. Available at: <https://www.nicd.ac.za/first-case-of-COVID-19-coronavirus-reported-in-sa/>. Accessed 8 February 2021.
4. Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. *Infect Dis Heal* 2020; 25:210–215.
5. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020; 26:672–675.
6. Qi L, Yang Y, Jiang D, et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. *Int J Infect Dis* 2020; 96:531–537.
7. Kim B, Sohn JW, Nam S, Sohn JW, Choi WS, Kim HS. Factors associated with the delayed termination of viral shedding in COVID-19 patients with mild severity in south korea. *Med* 2020; 56:1–11.
8. Lee S, Kim T, Lee E, et al. Clinical Course and Molecular Viral Shedding among Asymptomatic and Symptomatic Patients with SARS-CoV-2 Infection in a Community

- Treatment Center in the Republic of Korea. *JAMA Intern Med* 2020; 180:1447–1452.
9. Miyamae Y, Hayashi T, Yonezawa H, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Tokyo, Japan. *Int J Infect Dis* 2020; 97:293–295.
 10. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw Open* 2021; 4:e2035057–e2035057.
 11. AlJishi JM, Alhajjaj AH, Alkhabbaz FL, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. *J Infect Public Health* 2021; 14:6–11.
 12. Kim B, Sohn JW, Nam S, Sohn JW, Choi WS, Kim HS. medicina Factors Associated with the Delayed Termination of Viral Shedding in COVID-19 Patients with Mild Severity in South Korea.
 13. Hu X, Xing Y, Jia J, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. *Sci Total Environ* 2020; 728:138812.
 14. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patients with COVID-19. *Sn Compr Clin Med* 2020; 2:1.
 15. National Institute for National Communicable Diseases. NOTIFIABLE MEDICAL CONDITIONS (NMC) CASE DEFINITIONS. 2020.
 16. Phillips SP, Wei X, Kwong JC, et al. Duration of SARS-CoV-2 shedding: A population-based, Canadian study. *PLoS One* 2021; 16:e0252217.
 17. Owusu D, Pomeroy MA, Lewis NM, et al. Persistent SARS-CoV-2 RNA Shedding

- Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19. *J Infect Dis* 2021; 30333:1–10.
18. Tegally H, Wilkinson E, Lessells RJ, et al. Sixteen novel lineages of SARS-CoV-2 in South Africa. *Nat Med* 2021; 27:440–446.
 19. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children Fare Better than Adults? *Indian J Pediatr* 2020; 87:537–546.
 20. Sanyaolu A, Okorie C, Marinkovic A, Patidar R. Comorbilidad y su impacto en pacientes con COVID-19. *SN Compr Clin Med* 2020; 2:1069–1076.
 21. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021 121 2021; 12:1–6.
 22. DeBiasi RL, Delaney M. Symptomatic and Asymptomatic Viral Shedding in Pediatric Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Under the Surface. *JAMA Pediatr* 2021; 175:16–18.
 23. Jones DL, Baluja MQ, Graham DW, et al. Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19. *Sci Total Environ* 2020; 749:141364.
 24. Guo M, Tao W, Flavell RA, Zhu S. Potential intestinal infection and faecal–oral transmission of SARS-CoV-2. *Nat Rev Gastroenterol Hepatol* 2021; 18:269–283.
 25. Li Q, Zheng X-S, Shen X-R, et al. Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19.
<https://doi.org/101080/2222175120201852058> 2020; 9:2571–2577.

26. Alsaud AE, Nair AP, Matarneh AS, et al. Case Report: Prolonged Viral Shedding in Six COVID-19 Patients. *Am J Trop Med Hyg* 2021; 104:1472.
27. Centers for Disease Control and Prevention (CDC). COVID-19 Quarantine and Isolation | CDC. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html>. Accessed 13 October 2021.

28. DEPARTMENT OF HEALTH. Government Gazette Staatskoerant. 2020.
29. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission from People without COVID-19 Symptoms. *JAMA Netw Open* 2021; 4:1–8.
30. Weinbergerova B, Mayer J, Hrabovsky S, et al. COVID-19's natural course among ambulatory monitored outpatients. *Sci Rep* 2021; 11:1–16.
31. Pandita A, Gillani FS, Shi Y, et al. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. *PLoS One* 2021; 16:1–15.
32. Pouw N, de Maat J van, Veerman K, et al. Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in the Netherlands: A retrospective cohort study. *PLoS One* 2021; 16:1–15.
33. Sandoval M, Nguyen DT, Vahidy FS, Graviss EA. Risk factors for severity of COVID-19 in hospital patients age 18-29 years. *PLoS One* 2021; 16:1–22.
34. Abraham SA, Tessema M, Defar A, et al. Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia. *PLoS One* 2020; 15:e0244269.
35. Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. *Eur Respir J* 2020; 56.
36. Zhou C, Zhang T, Ren H, et al. Impact of age on duration of viral RNA shedding in patients with COVID-19. *Aging (Albany NY)* 2020; 12:22399–22404.
37. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in

- patients with COVID-19 Kaijin. 2020; :1–27.
38. Stehlik P, Alcorn K, Jones A, Schlebusch S, Wattiaux A, Henry DA. Repeat testing for SARS-CoV-2: persistence of viral RNA is common, and clearance is slower in older people. *Med J Aust* 2021; 214:468–470.
 39. Ji J, Zhang J, Shao Z, Xie Q, Zhong L, Liu Z. Glucocorticoid therapy does not delay viral clearance in COVID-19 patients. *Crit Care* 2020; 24:2–5.
 40. Chen X, Zhang Y, Zhu B, et al. Associations of Clinical Characteristics and Antiviral Drugs with Viral RNA Clearance in Patients with COVID-19 in Guangzhou, China. *SSRN Electron J* 2020;

TABLES

Table 1: Baseline characteristics of COVID-19 patients in South Africa, 2020

	Number of cases (n)	Percentage (%)
Age Group (years)		
0-14	46	1.7
15-24	172	6.3
25-34	516	18.8
35-44	630	22.9
45-54	547	19.9
55-64	418	15.2
65+	419	15.3
Sex		
Male	1,456	52.9
Female	1,291	46.9
Unknown	5	0.2
Admission status		
Inpatient	1,099	39.9
Outpatient	1,653	60.1
Province		
Eastern Cape	283	10.3
Free State	70	2.5
Gauteng	987	35.9
KwaZulu-Natal	603	21.9
Limpopo	94	3.4
Mpumalanga	95	3.5
North West	94	3.4
Northern Cape	39	1.4

Western Cape	487	17.7
Number of positive tests		
2	255	9.3
3	2,057	74.7
4	314	11.4
5	86	3.1
6	20	0.7
7	12	0.4
8	3	0.1
9	4	0.2
11	1	0.04

Table 2: Shedding time of laboratory-confirmed COVID-19 cases in South Africa, 2020

	Number of cases n(%)	Median (Range)
Overall shedding time	2 752 (100)	17 (1-128)
Age Group (years)		
0-14	46 (1.7)	14 (1-72)
15-24	172 (6.3)	16 (1-56)
25-34	516 (18.8)	18 (1-128)
35-44	630 (22.9)	17 (1-78)
45-54	547 (19.9)	17 (1-84)
55-64	418(15.2)	15 (1-94)
65+	419 (15.3)	16 (1-108)
Sex		
Male	1,456 (53)	16 (1-128)
Female	1,291 (47)	17 (1-94)
Admission status		
Inpatient	1,099 (39.9)	16 (1-108)
Outpatient	1,653 (60.1)	17 (1-128)
Province		
Eastern Cape	283 (10.3)	15 (1-56)
Free State	70 (2.5)	16 (1-67)
Gauteng	987 (35.9)	17 (1-128)
KwaZulu-Natal	603 (21.9)	17 (1-84)
Limpopo	94 (3.4)	21 (1-39)
Mpumalanga	95 (3.5)	20 (1-78)
North West	94 (3.4)	16 (1-54)
Northern Cape	39 (1.4)	16 (1-51)
Western Cape	487 (17.7)	17 (1-84)

Table 3: Univariate and multivariate analysis of factors affecting viral shedding time in COVID-19 patients in South Africa, 2020

	Bivariate			Multivariate		
	Coefficient	95%CI	P-value	Coefficient	95%CI	P-value
Age Groups (years)						-
0-14		Ref*				
15-24	-0.2	-0.6 - 0.2	0.376			
25-34	-0.01	-0.4 - 0.4	0.952			
35-44	0.1	-0.3- 0.5	0.696			
45-54	0.03	-0.4 - 0.4	0.870			
55-64	-0.1	-0.5- 0.3	0.488			
65+	-0.1	- 0.5 – 0.3	0.506			
Sex						-
Male	-0.3	-0.1 - 0.07	0.576			
Female		Ref*				
Admission status				-0.1	-0.2- -0.03	0.014
Inpatient	-0.1	-0.2 - -0.04	0.007			
Outpatient		Ref*				
Province						-
Eastern Cape		Ref*				
Free State	0.2	-0.2 - 0.5	0.339			
Gauteng	0.4	0.2 - 0.6	<0.001			
KwaZulu-Natal	0.3	0.1 - 0.5	<0.001			
Limpopo	0.6	0.3 - 0.9	<0.001			
Mpumalanga	0.5	0.2 - 0.8	0.002			
North West	0.4	0.1 - 0.7	0.012			
Northern Cape	0.04	-0.4 - 0.5	0.857			

Western Cape	0.3	0.1 - 0.5	0.001			
p-values – overall p-values for each exposure variable in the model, CI – Confidence Intervals Bivariate analysis, Adjusted - Multivariable analysis, Ref - Reference category - Not included in the final model because it is not significant ($p > 0.005$)						

FIGURE LEGENDS

Figure 1: Flow chart showing the participant selection process.

Figure 2: Distribution of shedding time of COVID-19 cases in South Africa by sex, 2020

Figure 3: Distribution of shedding time by age group (years) in South Africa by sex, 2020

Figure 1




Figure 2





Figure 3



CHAPTER 3: EXTENDED METHODS

This chapter presents additional research materials and methods that were not included in the manuscript due to the manuscript word count. These include record linkage and ethical considerations.

3.1 Record linkage

We applied a deterministic method to identify repeat test results from the same individuals and to link patients between the NMCList and DATCOV databases. The national identity or passport number was used as the linking variable. The linkage helped us determine patients who were admitted and who were not.

3.2 Ethical Considerations

For further permission to use COVID-19 surveillance data, we obtained ethical approval for the NMC surveillance system from the Human Research Ethics Committee at the University of the Witwatersrand (Approval number: M160667). Privacy of participants was ensured by removing personal identifiers (name, surname, ID number, telephone number, address) and using the unique identifier in the NMCSS line list database. The study data was stored on a password-protected computer and data was only accessible to the study team.

CHAPTER 4: EXTENDED RESULTS

This chapter presents additional findings of the study. The results are presented in percentages and a chart. We provide analysis and interpretation of findings based on the results of the statistical analysis performed.

In the manuscript, we reported that the median number of tests done by COVID-19 patients in our study was 3. Patients who had tested 3 times accounted for 75% (2057/ 2752) of the study population. The highest number of tests done was 11 and were done by 1 patient who was an inpatient. Inpatients had the highest numbers of tests conducted compared to outpatients, with 6 tests done by 65%, 7 tests (91.7%), 8 tests (66.6%), 9 and 11 tests done by inpatients only

(Figure 4.1).




Figure 4.1: Number of positive test results by COVID-19 admission status (inpatients patients and Outpatients) in South Africa, 2020

CHAPTER 5: OVERALL DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS

This chapter presents the main findings of the study. The results are presented in percentages, charts and tables. We provide analysis and interpretation of findings based on the results of the statistical analysis performed.

5.1 DISCUSSION

Recent guidelines in South Africa states that COVID-19 retesting after the isolation period is not needed¹. These guidelines were set on the basis that the presence of a detectable virus on a positive case does not necessarily indicate infectiousness. Even though continuous positivity from a PCR-test is not used to indicate continuous infectivity as assumed at the beginning of the pandemic, an RT-PCR test is still the most reliable for SARS-CoV-2 detection and diagnosis². For infection control, symptom and test-based strategies are used in different settings. Symptoms based strategy is done by calculating time passed from symptom onset and test-based strategy makes the use of a negative SARS-CoV-2 RT-PCR result. Furthermore, other factors are used to determine virus transmissibility positivity besides the use of viral load.

Viral shedding time varied within provinces across the country. Eastern Cape observed the shortest shedding time with a median of 15 days. Free State, North West and Northern Cape had a shedding time with a median of 16 days. They were followed by Gauteng, KwaZulu-Natal and Western Cape with a median of 17 days. Mpumalanga and Limpopo observed the highest shedding times with a median of 20 and 21 days, respectively. From the literature explored, factors associated with shedding time may differ according to the setting. This is evident in studies that were done in other countries and regions where we observed varying shedding durations. For example, the median shedding time in Changsha was (17 days)³, Singapore (12 days)⁴, Ethiopia (19 days)⁵, Tianjin (17 days)⁶ and Netherlands (8 days)⁷. This finding is similar to a study conducted in Germany that reported an association of viral shedding with disease severity which was defined by whether a patient was on mechanical ventilation or not⁸. Whereas Free State and Northern Cape were not statistically significant. Eastern Cape was used as a reference group. The difference in shedding time among provinces could be due to varying socioeconomic status and age distribution.

5.2 LIMITATIONS

In the manuscript, we mentioned the lack of clinical information from the data obtained from the NMCList and the DATCOV system. Although our data contained inpatients and outpatients, we could not report disease severity due to the lack of supporting information such as treatment given to patients. Our study contained a small sample of children, making it hard to generalize the findings of shedding time among children. Since we could not measure viral shedding before testing or before symptoms onset, we assumed that the viral shedding began on the date of symptom onset or date of specimen collection. This could have led to an underestimation of viral shedding time. This study only included cases that tested using an RT-PCR test and excluded cases that were tested using antigen tests. As a result, it is possible that our study might have underestimated shedding time within the population. Furthermore, we only addressed viral shedding time from the upper respiratory specimen sampled from the oropharyngeal and nasopharyngeal. With studies showing that cases also shed the virus using other channels such as feces and urine, we may need to compare shedding time from our study with shedding time from other studies that estimated shedding time using other routes. Since our study used the RT-PCR test, we need to consider the fact that there is a possibility that the positive SAR-CoV-2 results detected on the test may not have a correlation with infectivity. Although our study had limitations, the study design used enabled us to obtain data across all provinces within the country and enabled us to obtain a bigger sample size that is representative of the population. Our study enabled us to explore multiple settings which reduces selection bias.

5.3 CONCLUSION

This study provided details on viral shedding time within the population of South Africa. Our study found a significant association between the hospital admission status of COVID-19 patients and shedding time. There was a 1-day difference in shedding time between hospitalized and outpatients. Therefore, there is a need to strengthen prevention and control strategies such as contact tracing as both hospitalized and outpatients can shed the virus for a similar duration. We discovered that factors such as province, age and sex were not associated with shedding time. The study showed that some people can shed the virus longer than others. Although prolonged shedding might not necessarily indicate infectiousness, individual patient monitoring and management is needed for patients with prolonged shedding. Furthermore, to control SARS-CoV-2 infection,

different approaches that can address transmission risk effectively in asymptomatic patients are required.

5.4 RECOMMENDATIONS

Our study only looked at four predictor variables (sex, admission status, age and province). We recommend that further studies be conducted, including more variables such as comorbidities, socio-economic status, level of education and vaccination status. Since continuous positivity might not necessarily mean infectivity, we recommend that future studies consider evaluating live viruses within the population and also do a following up on cases with prolonged shedding to assess their contacts. This can assist in figuring out infectivity and can be used to inform isolation and quarantine requirements. We also recommend that studies evaluate the impacts of possible symptom recrudescence on shedding time and its impacts on SARS-COV-2 transmission.

REFERENCES

1. DEPARTMENT OF HEALTH. Government Gazette Staatskoerant. Vol. 583, Government Gazette. 2020.
2. Centers for Disease Control and Prevention (CDC). SARS | Guidance | Lab | Diagnostic Assays in Community Preparedness and Response | CDC [Internet]. [cited 2021 Oct 26]. Available from: <https://www.cdc.gov/sars/guidance/f-lab/assays.html>
3. Qi L, Yang Y, Jiang D, Tu C, Wan L, Chen X, et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. *Int J Infect Dis*. 2020;96:531–7.
4. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA*. 2020 Apr 21;323(15):1488–94.
5. Abraham SA, Tessema M, Defar A, Hussen A, Ejeta E, Demoz G, et al. Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia. *PLoS One*. 2020 Dec 1;15(12):e0244269.
6. Han J, Shi LX, Xie Y, Zhang YJ, Huang SP, Li JG, et al. Analysis of factors affecting the prognosis of COVID-19 patients and viral shedding duration. *Epidemiol Infect*. 2020;148.
7. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021 121. 2021 Jan 11;12(1):1–6.
8. Weinbergerova B, Mayer J, Hrabovsky S, Novakova Z, Pospisil Z, Martykanova L, et al. COVID-19's natural course among ambulatory monitored outpatients. *Sci Rep*. 2021;11(1):1–16.

Appendix 1: Plagiarism declaration



Appendix 2: Conference Abstract

 	
CPHIA 2021 (2021) 193 Track 1-Epidemiology of SARS-COV-2, virology, prevention and clinical management	
Estimation of Shedding Time in Laboratory-confirmed COVID-19 Cases in South Africa, 2020	
Applicant details	
Institutional Affiliation	National Institute for Communicable Diseases
Abstract details	
I confirm that I have read the abstract submission instructions and agree to the terms and conditions for CPHIA 2021 abstract applicants.	☒
First Name	Carroll
Last Name	Tshabane
Title	Ms.
Gender	☒ Female
Age	☒ 25-35
Do you have a PhD?	☒ No
Highest Educational Qualification	Masters
Country	South Africa
Email	ctshabane@gmail.com
Phone Number	+27612588731

Abstract Title

Estimation of Shedding Time in Laboratory-confirmed COVID-19 Cases in South Africa, 2020

Has this abstract been presented or published before? ☒ No

Keywords

COVID-19, SARS-CoV-2, laboratory-confirmed, shedding time, PCR

Lead Author ☐ Carroll Tshabane

Co-author(s)

Nkengafac Villyen Motaze, Hetani Mdose, Lazarus Kuonza

Research Year ☒ 2021

Introduction/Background

South Africa recorded its first COVID-19 case on 5 March 2020 and continues to report the largest number of cases in Africa. Determining viral shedding time is crucial in understanding COVID-19 transmission dynamics in South Africa. We aimed to estimate viral shedding time among laboratory-confirmed COVID-19 cases in South Africa.

Methods

We performed a cross-sectional analytic study using COVID-19 data collected in 2020, obtained from the NMCList and DATCOV systems. These platforms report laboratory-confirmed and hospitalized COVID-19 patients, respectively. The study consisted of laboratory-confirmed COVID-19 patients with repeat positive PCR tests (at least two positive PCR test results) and who subsequently tested negative. We defined shedding time as the period from the first positive PCR test to the last positive test prior to a first negative PCR test result. To determine the association between shedding time and predictor variables, multivariate analysis was conducted and a p-value <0.05 was considered statistically significant.

Results

We included 2752 cases. About 39.9% (1099/2752) of participants were inpatients and 60.1% (1653/2752) outpatients. The median shedding time was 17 days (range: 1–128). There was no significant difference in shedding time between males (median: 16 days, range: 1–128) and females (median: 17 days, range: 1–94) and between inpatients (median: 16 days, range: 1–108) and outpatients (median: 17 days, range: 1–128). Individuals aged 0–4 years had the lowest shedding time (median: 14 days, range: 1–72). After adjusting for age, sex and province, shedding time was shorter for admitted cases compared to outpatients (coefficient: -0.14, CI: -0.24 – -0.03, P-value: 0.014).

Impact

Our results will assist in refining COVID-19 infection control strategies and assist in the interpretation of repeat positive COVID-19 PCR tests over time. These results may also be used in facilitating early treatment and intervention, leading to a decrease in the incidence and mortality due to coronavirus disease.

Conclusion

The duration of viral shedding within the population of South Africa varies from 1 to 128 days. Admission status is associated with SARS-CoV-2 shedding time. Our findings indicate that infection control strategies should take into account factors affecting shedding time such as disease severity.

Appendix 3: Conference Attendance certificate



Appendix 4: Turnitin Report

Thesis document2.pdf			
ORIGINALITY REPORT			
12%	9%	8%	1%
SIMILARITY INDEX	INTERNET SOURCES	PUBLICATIONS	STUDENT PAPERS
PRIMARY SOURCES			
1	Www.esp.org Internet Source	1%	
2	Emrah Kılıçaslan, Işıl Erdoğan Özunal, Tayfun Elibol, Erman Öztürk. "Are Hematologic Patients Trojan Horse for COVID-19?", Indian Journal of Hematology and Blood Transfusion, 2021 Publication	1%	
3	www.mdpi.com Internet Source	<1%	
4	www.cambridge.org Internet Source	<1%	
5	www.researchsquare.com Internet Source	<1%	
6	Mahnaz Tashakori, Ahmad Jamalizadeh, Mohsen Nejad-Ghaderi, Maryam Hadavi et al. "Decreased Copper/Selenium Ratio Among Non-Responder Healthcare Workers to SARS-CoV-2: An Evidence of High Copper/Selenium Ratio Effects on the Immune Response to	<1%	

Appendix 5: Ethics clearance certificates

UNIVERSITY OF THE
WITWATERSRAND
JOHANNESBURG

R49 Ma C Tshabane

HUMAN RESEARCH ETHICS COMMITTEE (MEDICAL)
CLEARANCE CERTIFICATE NO. M210443

NAME: Ma C Tshabane
(Principal Investigator)

DEPARTMENT: School of Public Health
Division of Epidemiology and Biostatistics
Medical School
University


PROJECT TITLE: Estimation of shedding time in laboratory-confirmed
COVID-19 cases in South Africa: A population-based
record linkage study, March-December 2020

DATE CONSIDERED: 2021/04/30

DECISION: Approved unconditionally

CONDITIONS:

SUPERVISOR: Messrs V Molapo and J. Kuenze

APPROVED BY: 
Dr CB Penny, Chairperson, HREC (Medical)

DATE OF APPROVAL: 2021/06/09

This Clearance Certificate is valid for 5 years from the date of approval. An extension may be applied for.

DECLARATION OF INVESTIGATORS

To be completed in duplicate and ONE COPY returned to the Research Office secretariat on the 3rd floor, Philip Tobias Building, Parktown, University of the Witwatersrand, Johannesburg.

I/we fully understand the conditions under which I am/we are authorized to carry out the above-mentioned research and I/we undertake to ensure compliance with these conditions. Should any departure be contemplated from the research protocol as approved, I/we undertake to submit details to the Committee. I agree to submit a yearly progress report. When a funder requires annual re-certification, the application date will be one year after the date when the study was initially reviewed. In this case, the study was initially reviewed in April and therefore reports and re-certification will be due in the month of April each year. Unreported changes to the study may invalidate the clearance given by the HREC (Medical).


Signature of Principal Investigator

29 June 2021
Date



Office of the Deputy Vice-Chancellor (Research and Innovation)

TO: The Executive Director
National Institute for Communicable Diseases
Sandringham

E-mail: AdrianP@nicd.ac.za

CC: Supervisor: Not applicable
☞
and <HREC-Medical Research Office@wits.ac.za>

FROM: Mr Iain Burns
Human Research Ethics Committee (Medical)
Tel: 011 717 1252

E-mail: Iain.Burns@wits.ac.za

DATE: 2021/08/05

REF: R14/49

PROTOCOL NO: **M210752** (This is your ethics application reference number. Please quote it in all enquiries, oral or written, relating to this study.)

PROJECT TITLE: *Essential communicable disease surveillance and outbreak investigation activities of the National Institute for Communicable Diseases (NICD)*

Please find attached the Clearance Certificate for the above project. I hope it goes well and that an article in a recognized publication comes out of it. This will reflect well on your professional standing and contribute to Government funding of the University.

Appendix 6: Clinical Infectious Diseases Guidelines

Available from:

https://academic.oup.com/cid/pages/Manuscript_Preparation#Manuscript%20format%20and%20structure

https://academic.oup.com/cid/pages/article_types#Major%20Articles

<https://academic.oup.com/cid/issue-pdf/40/1/859089>

MANUSCRIPT FORMAT AND STRUCTURE

Major Articles

Report clinically relevant investigations or observations within CID s scope of interests.

Format guide:

- Word limit: 3000 words (excluding the abstract and references).
- Key points should be summarized on the title page in 40-words or less.
- References: 40 or less.
- Abstract: Up to 250 words, structured using the headings Background, Methods, Results and Conclusions.
- Tables/Figures: Data in the text should not be repeated extensively in tables or figures.

Please refer to a recent issue of Clinical Infectious Diseases for guidance on style and layout of articles. Also refer to the Article type section for guidance on relevant information for each article type.

Manuscript Submission

Clinical Infectious Diseases: Open Access follows a prescribed set of article types with a specific format for manuscript. Type the entire manuscript, including figure legends, tables, and references, in font 12, in Times New Roman, double-spaced using Microsoft Word. Leave 1-inch margins on all sides. Manuscripts should be written succinctly and should cite select references that are directly relevant. For guidance on length of each article, see section on article types below.

File Formats

The preferred format for submitting manuscripts online is Microsoft Word (.doc files). PDF files are not acceptable for submission.

File Contents

Manuscript .doc submissions are preferred as a single file, except for figures, which can be uploaded separately. You must also submit a cover letter in a second file, in the same format as your main file. Videos must be submitted in the .mp4 format. For each video, please submit a still image captured from the .mp4 file; this image will appear as a printable figure with the article. A video must have a legend that will appear with the still image. If you wish to submit a video, please consult with the CID editorial office for further details.

Manuscript Preparation

Manuscripts should be double-spaced throughout, including the references and the table and figure legends, with 1-inch margins on each side. All pages, except for the figures, should be numbered in the lower right-hand corner of the page, with the title page as page 1. The recommended layout is as follows: title page, abstract, text, acknowledgments, references, tables, figure legends, and figures.

Title Page

All manuscripts, including Correspondence, should have a title page that includes the following information:

1. A concise, informative title
2. The names and affiliations of all authors. The first name, initial(s), and surname of each author should be followed by his or her department, institution, city, and country.
3. Up to 5 keywords
4. A running title of no more than 40 characters and spaces
5. The complete contact information for both the corresponding and alternate corresponding authors.
6. Major Articles, Reviews, and Viewpoints should also include a 40-word summary of the article's main point.

It is editorial policy to list only one author for correspondence. We do not accept co-first authors, nor co-corresponding authors. However, it is acceptable to state that “author X, author Y, etc. contributed equally to this manuscript.”

Any changes of address may be given next to the Affiliations or in the Acknowledgments. Any deletions or additions to the author list after submission of the paper must be submitted in writing, and signed by all authors.

Abstract

The second page of the manuscript should contain the Abstract. Please refer to the Article Type for Abstract formats. The Abstract should be comprehensible to readers before they have read the paper and should not contain reference citations.

Multimedia Abstracts

Authors of the following article types are allowed to consider including a graphical abstract or video abstract as part of the article, in addition to the text abstract.

Major Articles

Review Articles

Brief Reports

Viewpoints

Multimedia abstracts are a visual summary of the main article findings and often take the form of graphical images or videos. They display in addition to the text abstract and offer readers a quick browsing method, in addition to providing you with an asset to share and discuss your findings. The abstract is considered a part of the article and should be submitted with the full article; they are peer reviewed and published online and in PDF.

Abbreviations

Non-standard abbreviations should be kept to a minimum. They should be defined at the first occurrence and introduced only where multiple use is made.

Text

Authors are encouraged to follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. They should strive for a concise article without excessive detail (word limits are specified under Categories of Articles). All but the shortest articles should have subheadings.

Funding

Details of all funding sources for the work in question should be given in a separate section entitled “Funding.” This should appear before the “Acknowledgment” section.

The following rules should be followed:

- The sentence should begin: “This work was supported by ...”
- The full official funding agency name should be given, ie “the National Cancer Institute at the National Institutes of Health” or simply “National Institutes of Health” not “NCI” (one of the 27 subinstitutions) or “NCI at NIH.” Please see here for a full RIN-approved list of UK funding agencies.
- Grant numbers should be complete and accurate and provided in brackets as follows: “[grant number ABX CDXXXXXX]”
- Multiple grant numbers should be separated by a comma as follows: “[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]”
- Agencies should be separated by a semi-colon (plus “and” before the last funding agency)
- Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number “to [author initials].”

An example is given here: “This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789].”

Crossref Funding Data Registry and CHORUS

In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about CHORUS, visit the CHORUS initiative.

Conflict of Interest

Please follow this link for further guidance on Conflict of Interests.

Acknowledgments

Personal acknowledgment should precede those of institutions of agencies. Any substantial assistance in preparing the manuscript—for example, in data retrieval or statistical analysis—other than by an author should be stated.

Please note that acknowledgment of funding bodies and declarations regarding conflicts of interest should be given in separate Funding and Conflicts of Interest sections, respectively.

Please follow this link for further guidance on Conflict of Interests.

References

EndNote and Reference Manager are software programs for publishing and managing references/bibliographies, which are available from Thomson Reuters. If you use EndNote or Reference Manager to facilitate referencing citations, this journal's style is available for use. The EndNote program and relevant information can be found here: <http://www.endnote.com/support/enstyles.asp>. Please follow the instructions on this page regarding purchasing, downloading, and using the software.

CID reference style is based on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals

Names of journals are abbreviated according to the List of Journals Indexed for Medline. Titles of journals not listed in Medline should be spelled out in full. References should be numbered consecutively as they appear in the text, with the numbers in brackets on the text line (e.g., [3, 7–9, 57]). References first cited in tables or figures should be in sequence with those in the text; for example, if table 1 is mentioned in the text after reference [8], the next new reference cited in table 1 will be reference [9]. Unpublished data should be cited in the text as (unpublished data), but not included in the references list. References to manuscripts submitted, but not yet accepted, should be cited in the text as (B Jones and L Smith, manuscript in preparation) and should not be included in the reference list. References to pre-prints are permitted but only where the final version of the paper has yet to be published in a journal. Citations of submitted manuscripts should include all authors involved. For references with >6 authors, the first 3 authors should be listed, followed by

et al. Reference to a doctoral dissertation should include the author, title, institution, location, year, and publication information, if published. For online resources, a URL and date accessed should be included. Accuracy of references is the responsibility of the authors.

The citation of journals, books, multi-author books, preprints (to be cited only where a final version of the paper has yet to be published in a journal), and articles published online should conform to the following examples:

- Gorecki DC, Monaco AP, Derry JMJ, Walker AP, Barnard, EA, Barnard, PJ. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. *Hum Mol Genet*, 1995 ; 155: 505-511.
- Francis V, Bastin M. (2000) Gene targeting in rat embryo fibroblasts promoted by the polyomavirus large T antigen. *Nucleic Acids Res* [in press].
- Maniatis T, Fritsch EF, Sambrook J. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1982 .
- Huynh TV, Young RA, Davis RW. DNA Cloning. In: Glover DM. *DNA Cloning - A Practical Approach*. Vol 1. Oxford, UK: IRL Press; 1988 :49-78.
- Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at: <http://www.aidsinfo.nih.org>. Accessed 24 April 2002.
- Lyon DJ, Cheng AFB, Norrby SR. Mechanisms of cefotaxime resistance in blood culture isolates of *Enterobacter* high prevalence of extended-spectrum β -lactamases [abstract C43]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:47.
- Pre-print example: Bar DZ, Atkatsch K, Tavares U, Erdos MR, Gruenbaum Y, Collins FS. Biotinylation by antibody recognition- A novel method for proximity labeling. *BioRxiv* 069187 [Preprint]. August 11, 2016 [cited 2017 Jan 12]. Available from: <https://doi.org/10.1101/069187>.

Tables

All tables should be on separate pages and accompanied by a title, and footnotes where necessary. The tables should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in parentheses at the top of each column and not repeated in each line of the table. Ditto signs are not used. Avoid overcrowding the tables and excessive words. The format of tables should be in keeping with that normally used by the journal; in particular, vertical lines, colored texts, and shading should not be used. Please be certain that the data given in tables are correct.

In a footnote to the table, all abbreviations used should be defined, unless otherwise defined in the text, excluding units of measure. Footnotes and accompanying explanatory material should be kept to a minimum. Footnotes should be placed below the table and designated by superscript lowercase letters (listed in order of location when the table is read horizontally). Each column must have a heading describing the data below, and units of measure must be clearly indicated for all data.

Please follow this link for further details on table formatting.

Figure Legends

These should be on a separate, numbered manuscript sheet. Define all symbols and abbreviations used in the figure. Figures and legends should be intelligible without reading the text of the manuscript.

Manuscript Details

Nomenclature

CID attempts to use the latest widely accepted nomenclature. See Bergey's Manual of Determinative Bacteriology (9th ed., revised, Williams & Wilkins, 1994) and Enzyme Nomenclature: Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes (Academic Press, 1992). Formal terms for virus families, genera, and species should be those approved by the International Committee on Taxonomy of Viruses; see Virus Taxonomy—The Classification and Nomenclature of Viruses: Seventh Report of the International Committee on Taxonomy of Viruses (Academic Press, 2000). This volume also includes standard abbreviations

for virus species. For names and abbreviations of chemical compounds, refer to the Merck Index (13th ed., Merck, 2001). The Editors appreciate the assistance of authors and readers who inform them of changes in nomenclature.

Human Genetic Nomenclature and Notation

For human genes, use genetic notation and symbols approved by the Human Gene Mapping Workshop (see Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. Guidelines for human gene nomenclature. *Genomics* 2002; 79:464–70). Human gene names and loci should be written in italicized capital letters and Arabic numerals. Human protein product names are not italicized. For human mutation nomenclature, see Antonarakis et al. (Recommendations for a nomenclature system for human gene mutations. *Hum Mutat* 1998; 11:1–3).

Human Single-Nucleotide Polymorphisms (SNPs)

For human genes, newly described SNPs should be submitted to an appropriate database, such as dbSNP, prior to submission of the revised manuscript. The identification numbers of previously recognized SNPs (rs numbers) or recently submitted SNPs (ss numbers) should be provided in the manuscript, if the number of SNPs is small, or submitted as supplemental online material, if the number is large.

Statistical analysis

The statistical analyses used should be identified both in the text and in all tables and figures where the results of statistical comparison are shown.

Units of measurement

The use of SI units is encouraged. All data should be expressed in metric units. Temperature should be expressed in degrees Celsius.

Journal Copyediting Style

Authors are referred to the AMA Manual of Style: A Guide for Authors and Editors (10th ed., Oxford University Press, 2007) and the Chicago Manual of Style (16th ed., University of Chicago Press, 2010). For commercially obtained products mentioned in the text, the full names of

manufacturers should be listed. Generic names of drugs and other chemical compounds should be used.

Language editing, if your first language is not English, to ensure that the academic content of your paper is fully understood by journal editors and reviewers is recommended, though optional. Language editing does not guarantee that your manuscript will be accepted for publication. Please follow this link for further information on this service. Several specialist language editing companies offer similar services and you can also use any of these. None of these services have been validated by CID, OUP, or IDSA. Authors are liable for all costs associated with such services.

Figures and Illustrations

Patient's identity must be removed in all figures (i.e., x-rays, MRIs, charts, photographs, etc.). Written informed consent is required from any potentially identifiable patient or legal representative, and should be presented in either the Methods section or the Acknowledgements.

Figures should also be numbered in the order of mention in the text and should appear at the end of the manuscript and references. Figures will not be relettered by the publisher. The journal reserves the right to reduce the size of illustrative material.

Formatting

Multipart figures should be submitted as a single file, with panels labeled within the image, rather than as multiple files. Letters, numbers, and symbols should be clear and of sufficient size to be legible when the figures are reduced. Photomicrographs should have internal scale markers. If the manuscript is accepted, the author will be required to supply high resolution figure files for production.

Save figure files in TIFF or EPS format, using CMYK colors, with fonts embedded. When creating figures, please make sure any embedded text is large enough to read. If figures contain miniscule characters such as numbers on a chart or graph, they will most likely be illegible in the final version.

Please follow this link and scroll down to Figures for useful information on preparing your figures for publication.

Halftone illustrations, photographs

Any photomicrographs, electron micrographs, or radiographs must be of high quality with respect to detail, contrast, and fineness of grain to withstand the inevitable loss of contrast and detail inherent in the printing process. Wherever possible, photographs should fit within the print area or within a column width. Photomicrographs should provide details of staining technique and a scale bar. Patients shown in photographs should have their identity concealed or should have given their written consent to publication. Please indicate the magnification by a bar on the photograph. Minimum resolutions are 300 d.p.i for color or tone images.

Line Drawings

All line drawings should have clear and sharp lines. No additional artwork, redrawing, or typesetting will be done. Therefore, all labeling should be done on the original line drawing. Faint shading and stippling could be lost upon reproduction and should be avoided. Line drawings must have a resolution of at least 600 d.p.i. at their final size.

Color Illustrations

Authors are required to pay the full cost of reproduction of color figures. For details see Clinical Infectious Diseases charges. If you require color reproduction of figures in the print journal you will be asked to approve the cost. An invoice will be issued at the time of publication.

Clinical Infectious Diseases also offers free reproduction of color figures in the online version (figures in the print version will appear in black and white). Figure captions must be suitable worded to apply to both the print and online versions of the article.

Permission to Reproduce Figures and Extracts

For a copyright prose work, it is recommended that permission is obtained for the use of extracts longer than 400 words; a series of extracting totally more than 800 words, or which any one extract is more than 300 words; or an extract or series of extract compromising one-quarter of the work or more.

Permission to reproduce copyright material, for print and online publication in perpetuity, must be cleared and if necessary paid for by the author; this includes applications and payments to DACS, ARS, and similar licensing agencies where appropriate. Evidence in writing that such permissions

have been secured from the rights-holder must be made available to the editors. It is also the author's responsibility to include acknowledgements as stipulated by the particular institutions. Oxford Journals can offer information and documentation to assist authors in securing print and online permissions: please see the Guidelines for Authors section.

Supplementary Data

Supplementary data is supporting material that cannot be included in the printed version for reasons of space and is not essential for inclusion in the full text of the manuscript but would nevertheless benefit the reader. The material should not be essential to understanding the conclusions of the paper but should contain data that is additional or complementary and directly relevant to the article content. Such information might include more detailed methods, extended data sets/data analysis, or additional figures or tables.

It is standard practice for appendices to be made available online only as supplementary material. All text and figures must be provided in suitable electronic formats. All material to be considered as supplementary material must be submitted at the same time as the main manuscript for peer review. It cannot be altered or replaced after the paper has been accepted for publication, and will not be edited. Files for supplementary data should be clearly marked as such and be accompanied by a summary of the file names and types. Also ensure that the supplementary material is referred to in the main manuscript where necessary, for example as "(see Supplementary Material)" or "(see Supplementary Figure 1)."

Please note that supplementary data will not be copyedited, so ensure that it is clearly and succinctly presented, and that the style of terms conforms with the rest of the paper. It cannot be altered or replaced after the paper has been accepted for publication.

Copyright and License

It is a condition of publication in Clinical Infectious Diseases that the authors grant an exclusive license to the journal's sponsoring society, the Infectious Diseases Society of America. This ensures that all of the necessary rights needed for publication of the article are in place including provision for any requests from third parties to reproduce the content to be as widely disseminated as possible. No article will be published unless the signed license has been received at Oxford Journals. Authors will be notified by the CID Editorial office when their article has been processed

to OUP Production. Within a few days, a license form link will be sent by OUP Production to the corresponding author. The first line of the email will read: "Welcome to Oxford Journals!" Please note that, in order for your article to publish, it is imperative that you visit the link provided and sign your License to Publish form as soon as possible. Without your signed consent, Oxford Journals cannot publish your article. The sooner your signature is received; the sooner your work can be disseminated. Any queries about the license form should be sent as soon as possible to Rights and permissions so that any issues can be resolved quickly and to avoid any delay in publication.

As part of the license agreement, authors may use their own material in other publications, provided that the journal is acknowledged as the original place of publication and Oxford University Press is acknowledged as the publisher.

Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright license to publish form.

Work submitted for publication must be original, previously unpublished, and not under consideration for publication elsewhere. If previously published figures, tables, or parts of text are to be included, the copyright-holder's permission must have been obtained prior to submission. For more information on how to obtain permissions, please consult Rights and Permissions.

Proofs

Authors are sent page proofs by email. To avoid delays in publication, proofs should be checked immediately and corrections, as well as answers to any queries, returned to the publishers as an annotated PDF via email or fax within 2 working days. Further details are supplied with the proof. It is the author's responsibility to check proofs thoroughly.

Excessive alterations in the proof stage may delay publication of the article to a subsequent issue. Authors who make extensive amendments to the text at the page-proof stage will be charged an additional fee.

Advance Access

Advance Access allows for papers to be published online soon after they have been accepted for publication, reducing the time between submission and publication. Advance Access articles are a

mix of accepted manuscripts, labeled as “Accepted Manuscripts,” and finalized manuscripts, labeled as “Corrected Proofs.” Posted Accepted Manuscripts have been accepted by the journal but have not been copyedited or formatted per journal style. Copyediting may lead to minor differences between the Accepted Manuscript and the Corrected Proof; there will be changes to the formatting and there may also be differences in the quality of the graphics. Appearance in Advance Access constitutes official publication, though the articles have not yet been paginated for inclusion in a specific issue of the journal. The Advance Access version can be cited by a unique DOI (Digital Object Identifier). When the Corrected Proof is paginated into an issue, it will then be removed from the Advance Access page.

Availability of Data and Materials

Where ethically feasible, Clinical Infectious Diseases strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. For information on general repositories for all data types, and a list of recommended repositories by subject area, please see Choosing where to archive your data.

Data Citation

Clinical Infectious Diseases supports the Force 11 Data Citation Principles and requires that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI). Data citations should include the minimum information recommended by DataCite:

- [dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier

*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list.

Appendix 7: Declaration- Candidate's contribution to manuscript

I, Carroll Tshabane, student number [2374447], declare that this Research Report is my own work and that I contributed adequately towards research findings published in the article which is included in my Research Report.

Signature of Student: c. tshabane

Date: 25 January 2022

Name of Primary Supervisor: Dr Lazarus Kuonza

Signature of Primary Supervisor: L Kuonza Date: 28 March 2022